Literature DB >> 12840060

Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.

Kimiyasu Egami1, Toyoaki Murohara, Toshifumi Shimada, Ken-Ichiro Sasaki, Satoshi Shintani, Takeshi Sugaya, Masahiro Ishii, Teiji Akagi, Hisao Ikeda, Toyojiro Matsuishi, Tsutomu Imaizumi.   

Abstract

Although the renin angiotensin system (RAS) is a major regulator of vascular homeostasis, the role of the RAS in tumor angiogenesis is little understood. Here we show that host angiotensin II (ATII) type 1 (AT1) receptor plays an important role in angiogenesis and growth of tumor cells engrafted in mice. Subcutaneous B16-F1 melanoma-induced angiogenesis as assessed by tissue capillary density and microangiography was prominent in WT mice but was reduced in AT1a receptor-deficient (AT1a-/-) mice. Consequently, tumor growth rate was significantly slower, and the mouse survival rate was greater, in AT1a-/- mice than in WT mice. Tumor growth was also reduced in WT mice treated with TCV-116, a selective blocker of AT1 receptor. Because the beta-galactosidase gene was inserted into the AT1a gene locus in AT1a-/- mice, the site of beta-galactosidase expression represents the AT1a receptor expression in these mutant mice. In tumor-implanted AT1a-/- mice, the major site of the beta-galactosidase expression was macrophages in tissues surrounding tumors. Moreover, the number of infiltrated macrophages was significantly lower in AT1a-/- mice than in WT mice, and double-immunofluorescence staining revealed that these macrophages expressed VEGF protein intensively. Therefore, the host ATII-AT1 receptor pathway supports tumor-associated macrophage infiltration, which results in enhanced tissue VEGF protein levels. The host ATII-AT1 receptor pathway thereby plays important roles in tumor-related angiogenesis and growth in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12840060      PMCID: PMC162282          DOI: 10.1172/JCI16645

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages.

Authors:  A Okamura; H Rakugi; M Ohishi; Y Yanagitani; S Takiuchi; K Moriguchi; P A Fennessy; J Higaki; T Ogihara
Journal:  J Hypertens       Date:  1999-04       Impact factor: 4.844

2.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 3.  Angiotensin II type 1 receptor blockers.

Authors:  M Burnier
Journal:  Circulation       Date:  2001-02-13       Impact factor: 29.690

4.  Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats.

Authors:  M Usui; K Egashira; H Tomita; M Koyanagi; M Katoh; H Shimokawa; M Takeya; T Yoshimura; K Matsushima; A Takeshita
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

5.  Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model.

Authors:  M Muramatsu; J Katada; I Hayashi; M Majima
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

6.  Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats.

Authors:  S Takeshita; H Tomiyama; N Yokoyama; Y Kawamura; T Furukawa; Y Ishigai; T Shibano; T Isshiki; T Sato
Journal:  Cardiovasc Res       Date:  2001-11       Impact factor: 10.787

7.  Host cyclooxygenase-2 modulates carcinoma growth.

Authors:  C S Williams; M Tsujii; J Reese; S K Dey; R N DuBois
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

8.  Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis.

Authors:  M J Gorrin-Rivas; S Arii; M Furutani; M Mizumoto; A Mori; K Hanaki; M Maeda; H Furuyama; Y Kondo; M Imamura
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

9.  Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis.

Authors:  Ken Sasaki; Toyoaki Murohara; Hisao Ikeda; Takeshi Sugaya; Toshifumi Shimada; Satoshi Shintani; Tsutomu Imaizumi
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

10.  Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis.

Authors:  Mamoru Fujita; Izumi Hayashi; Shohei Yamashina; Moritoshi Itoman; Masataka Majima
Journal:  Biochem Biophys Res Commun       Date:  2002-06-07       Impact factor: 3.575

View more
  105 in total

Review 1.  Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about?

Authors:  Vadim Tchaikovski; Gregory Y H Lip
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 2.  Applied Healthspan engineering.

Authors:  James W Larrick; Andrew Mendelsohn
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

Review 3.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

Authors:  Rana R McKay; Gustavo E Rodriguez; Xun Lin; Marina D Kaymakcalan; Ole-Petter R Hamnvik; Venkata S Sabbisetti; Rupal S Bhatt; Ronit Simantov; Toni K Choueiri
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

5.  Expression of angiotensin II type 1 and type 2 receptor mRNAs in the gastric mucosa of Helicobacter pylori-infected Mongolian gerbils.

Authors:  Mitsushige Sugimoto; Tomoyuki Ohno; Yoshio Yamaoka
Journal:  J Gastroenterol       Date:  2011-07-13       Impact factor: 7.527

Review 6.  Novel therapeutic approaches for progressive renal disorders by targeting glomerular component mesangial and endothelial cells.

Authors:  Yohei Maeshima
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

7.  Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.

Authors:  Hiroji Uemura; Hisashi Hasumi; Takashi Kawahara; Shinpei Sugiura; Yasuhide Miyoshi; Noboru Nakaigawa; Jun-ichi Teranishi; Kazumi Noguchi; Hitoshi Ishiguro; Yoshinobu Kubota
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.402

8.  Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

Authors:  Sho-ichi Yamagishi; Riichiro Abe; Yosuke Inagaki; Kazuo Nakamura; Hiroshi Sugawara; Daisuke Inokuma; Hideki Nakamura; Tadamichi Shimizu; Masayoshi Takeuchi; Akihiko Yoshimura; Richard Bucala; Hiroshi Shimizu; Tsutomu Imaizumi
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  ATAC-ing the mechanisms of renin regulation.

Authors:  Steven D Crowley
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

Review 10.  Stimulation of endothelial progenitor cells: a new putative effect of several cardiovascular drugs.

Authors:  Natália António; Rosa Fernandes; Noela Rodriguez-Losada; Manuel F Jiménez-Navarro; Artur Paiva; Eduardo de Teresa Galván; Lino Gonçalves; Carlos Fontes Ribeiro; Luís A Providência
Journal:  Eur J Clin Pharmacol       Date:  2009-12-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.